Meeting
2017 ASCO Annual Meeting
Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
Authors
Sara Michele Federico
St. Jude Children's Research Hospital, Memphis, TN
Sara Michele Federico , Elizabeth Stewart , Jamie L. Coleman , Michael William Bishop , Victor M. Santana , Catherine Lam , Dana Hawkins , Jianrong Wu , Shenghua Mao , David Ross Goshorn , Alberto S. Pappo , Michael A. Dyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02392793
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10542)
DOI
10.1200/JCO.2017.35.15_suppl.10542
Abstract #
10542
Poster Bd #
299
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
First Author: Kieuhoa T. Vo
Poster
2019 ASCO Annual Meeting
Pooled analysis of phase I dose-escalation and dose cohort expansion studies of IMP4297, a novel PARP inhibitor, in Chinese and Australian patients with advanced solid tumors.
First Author: Junning Cao
Poster
2019 ASCO Annual Meeting
AcSé-ESMART: “European Proof of Concept Therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory Tumors in children and adolescents” –ARM D: Olaparib and Irinotecan.
First Author: Susanne Andrea Gatz
Poster
2017 ASCO Annual Meeting
A phase I study of carboplatin and talazoparib in patients with and without DNA repair mutations.
First Author: Mallika Sachdev Dhawan